Příprava protinádorových vakcín na bázi nové generace dendritických buněk pro potřeby klinických studií

Title in English Preparation of anti-tumour vaccines based on new generation dendritic cells for use of clinical studies
Authors

SKÁLOVÁ Kateřina MACKOVÁ Klára MUŽÍKOVÁ Jana NOVOTNÁ Dana VIDLÁKOVÁ Petra SMEJKALOVÁ Jana MICHÁLEK Jaroslav

Year of publication 2009
Type Conference abstract
MU Faculty or unit

Faculty of Medicine

Citation
Description One of the approaches in cancer treatment is vaccination with autologous dendritic cells (DC). DC are antigen-presenting cells. During the vaccine preparation the DC are loaded with lysate of patients tumour tissue. DC then present the tumour antigens to the T-cells in vivo and stimulate anti-tumour immune response. New generation of the vaccines is based on DC producing interleukin 12 (IL-12), which polarizes immune response towards Th1 helper T-cells and cytotoxic T-cells. We have recently validated the method of new generation DC preparation for the use of clinical studies. Whole process of vaccine preparation proceeds according to good manufacturing practice in sterile conditions of working site certified for drug product manufacture - the GMP facilities of Masaryk University in Brno.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info